GELS (Gelteq) Notes Receivable: $0.00 Mil (As of Jun. 2025)


GELS Gelteq Ltd GELS
10 GF Score
Price $0.65
! 3 Warning Signs
View Full Analysis

What is Gelteq Notes Receivable?

Gelteq GELS +2.16% 10 Notes Receivable is $0.00 Mil as of Jun. 2025. GuruFocus rates GELS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Gelteq's Notes Receivable for the quarter that ended in Jun. 2025 was $0.00 Mil.

Gelteq Notes Receivable Historical Data

* Premium members only.

The historical data trend for Gelteq's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelteq Notes Receivable Chart

Gelteq Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Gelteq Semi-Annual Data
Jun20 Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
GELS
10GF Score
Gelteq Ltd GELS
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gelteq Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Gelteq (GELS) has a Notes Receivable of $0.00 Mil as of Jun. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Gelteq and its competitors.
Is Gelteq's Notes Receivable too high?
Gelteq's current Notes Receivable is $0.00 Mil. Overall, Gelteq has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's Notes Receivable compare to YCBD and AKAN?
Gelteq's Notes Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Gelteq and its competitors. Gelteq's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Gelteq's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Gelteq (GELS), the current Notes Receivable is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelteq Business Description

Address 644 Chapel Street, Level 19, South Yarra, VIC, AUS, 3141
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
10GF Score

Get the complete analysis for GELS

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price